# CJC-1295 Side Effects in the Research Literature | Online Edition > CJC-1295 side effects reported in published Phase 1 and observational literature: flushing, headache, injection-site reaction, water retention, transient paresthesia; long-term safety undefined. What the published Phase 1 studies, the terminated Phase 2 trial, and the observational record have reported as adverse effects of CJC-1295 — short-term, medium-term, and the long-term safety gap. ## Reported adverse effects CJC-1295 side effects as reported in the published clinical record and the observational research literature cluster into a small, consistent set. Most-reported short-term effects: facial flushing, mild headache, injection-site redness, transient water retention, occasional numbness or tingling, and occasional dizziness [3][15]. These are the standard short-term adverse effects associated with GH-axis stimulation broadly and are consistent across the published Phase 1 record [3][4]. The Teichman 2006 Phase 1 ascending-dose study reported no serious adverse reactions at the tested doses in healthy adults [3]. The Ionescu 2006 continuous-stimulation study likewise reported standard short-term effects without serious adverse events at 60 or 90 µg/kg [4]. The principal serious-event record on CJC-1295 is the 2006 fatal myocardial infarction in the terminated Phase 2 lipodystrophy trial (NCT00267527), discussed in its own section below [5]. ## More serious concerns flagged in the literature Sustained elevation of growth hormone and IGF-1 — the precise pharmacological signature of CJC-1295-DAC — raises specific theoretical concerns drawn from the broader endocrinology of GH excess. A 2024 review of GH / IGF-1 / insulin interplay summarizes the mechanism: chronic GH and IGF-1 elevation suppresses the antilipolytic action of insulin, drives lipotoxicity, and promotes hepatic and peripheral insulin resistance with compensatory hyperinsulinemia [15]. The clinical model for chronic GH/IGF-1 elevation is acromegaly, where the metabolic disturbance is well documented [15]. The principal serious-event record on CJC-1295 itself is the 2006 fatal myocardial infarction in a Phase 2 trial participant in Argentina (NCT00267527), which halted industry development [5][9]. The site investigator's attributed cause was asymptomatic coronary artery disease with plaque rupture, judged most likely unrelated to the peptide; the sponsor concluded the event was unlikely directly related but discontinued the program nonetheless [5]. Long-term human safety data on CJC-1295 is absent. ## Safety profile in published research Short-term safety in the two published Phase 1 studies (Teichman 2006, Ionescu 2006) was reported as acceptable at the tested doses, with the standard short-term adverse-effect profile described above and no serious adverse reactions [3][4]. Long-term safety is undefined — no completed Phase 2 or Phase 3 trial has produced multi-month or multi-year safety data in humans. The 2006 Phase 2 trial that would have produced that record was terminated [5][9]. Regulatory status reflects this gap. CJC-1295 is not approved by the FDA, the EMA, or any other regulator for any therapeutic indication [16]. It is classed as an Investigational New Drug in the United States. The FDA removed CJC-1295 and ipamorelin acetate from Section 503A Category 2 (bulk drug substances under evaluation for compounding) effective 27 September 2024, leaving both compounds in regulatory limbo — not Category 1 (permitted) and no longer Category 2 (under evaluation) [16]. The World Anti-Doping Agency prohibits CJC-1295 under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics), in and out of competition [7]. ## Stacked side-effect profile with ipamorelin The CJC-1295 + ipamorelin paired protocol carries the side-effect profile of CJC-1295 alone plus the ipamorelin-specific profile [12]. Ipamorelin's distinguishing pharmacological feature is selectivity — it releases GH without significantly elevating ACTH, cortisol, or prolactin even at high doses [12]. Reported short-term effects added by ipamorelin in the observational research literature include transient hunger (consistent with its ghrelin-receptor agonism), occasional mild GI symptoms, and the standard injection-site reactions [12]. No completed Phase 2 or Phase 3 trial has formally evaluated the paired CJC-1295 + ipamorelin protocol in humans against placebo control. The paired safety record is observational and preclinical. Long-term safety of the paired protocol is undefined. ## Combinations cautioned against in the literature Published clinical reviews caution against specific combinations involving CJC-1295. Stacking multiple GHRH analogs — for example CJC-1295-DAC together with sermorelin or tesamorelin — amplifies GH/IGF-1 elevation and is cautioned against on additive insulin-resistance and proliferative-risk grounds [15]. Pairing CJC-1295 with exogenous insulin or anabolic agents in the same protocol is similarly flagged, on the same grounds [15]. The principle the literature supports is conservative receptor-pathway-counting: one mechanism of GH-axis stimulation at a time, with the GH-axis biomarkers (GH, IGF-1) monitored; chronic stacking of multiple GH-stimulation pathways without monitoring is cautioned against [15]. ## References [3] Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805. https://pubmed.ncbi.nlm.nih.gov/16352683/ [4] Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology and Metabolism. 2006;91(12):4792-4797. https://pubmed.ncbi.nlm.nih.gov/17018654/ [5] aidsmap editorial team. Lipodystrophy study halted after patient death (news report on ConjuChem CJC-1295 Phase 2 trial NCT00267527). aidsmap (NAM Publications). 2006. https://www.aidsmap.com/news/jul-2006/lipodystrophy-study-halted-after-patient-death [7] World Anti-Doping Agency. The Prohibited List - Section S2: Peptide Hormones, Growth Factors, Related Substances and Mimetics. WADA Prohibited List. 2024. https://www.wada-ama.org/en/prohibited-list [9] ConjuChem Biotechnologies. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527). ClinicalTrials.gov. 2005. https://clinicaltrials.gov/study/NCT00267527 [12] Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561. https://academic.oup.com/ejendo/article-abstract/139/5/552/6748390 [15] Vijayakumar A, et al. The fascinating interplay between growth hormone, insulin-like growth factor-1, and insulin. Endocrinology and Metabolism (Korea). 2024. https://www.e-enm.org/journal/view.php?doi=10.3803%2FEnM.2024.101 [16] FDA. Section 503A Category 2 removal of CJC-1295 and ipamorelin acetate, effective 27 September 2024. FDA Federal Register / Docket FDA-2024-N-4777. 2024. https://downloads.regulations.gov/FDA-2024-N-4777-0002/attachment_7.pdf --- An online journal-supplement reading of the CJC-1295 research record — neo-grotesque on cool white, cobalt-ruled, citation-explicit, and not a vendor, a clinic, or a prescription.